LeMaitre Vascular (NASDAQ:LMAT) Stock Rating Lowered by Oppenheimer

LeMaitre Vascular (NASDAQ:LMAT) was downgraded by Oppenheimer from an “outperform” rating to a “market perform” rating in a research report issued on Friday, MarketBeat reports.

Several other equities research analysts have also weighed in on the company. Wells Fargo & Company began coverage on LeMaitre Vascular in a research report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 price target on the stock. Barrington Research cut LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday. Finally, StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Five research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, LeMaitre Vascular has an average rating of “Moderate Buy” and an average price target of $95.25.

LeMaitre Vascular Stock Down 8.1 %

NASDAQ LMAT opened at $91.85 on Friday. LeMaitre Vascular has a twelve month low of $62.39 and a twelve month high of $109.58. The firm has a market capitalization of $2.07 billion, a PE ratio of 50.19, a P/E/G ratio of 2.22 and a beta of 0.96. The stock’s 50 day moving average is $96.89 and its 200 day moving average is $94.73.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, meeting the consensus estimate of $0.49. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company had revenue of $55.81 million for the quarter, compared to analyst estimates of $55.99 million. On average, research analysts anticipate that LeMaitre Vascular will post 1.94 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of LMAT. Raymond James Financial Inc. purchased a new position in shares of LeMaitre Vascular in the fourth quarter worth $14,900,000. Rockefeller Capital Management L.P. purchased a new position in shares of LeMaitre Vascular in the fourth quarter worth $7,787,000. Segall Bryant & Hamill LLC purchased a new position in shares of LeMaitre Vascular in the fourth quarter worth $5,446,000. Invesco Ltd. raised its stake in shares of LeMaitre Vascular by 50.5% in the fourth quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier’s stock worth $16,124,000 after purchasing an additional 58,720 shares during the last quarter. Finally, DF Dent & Co. Inc. raised its stake in shares of LeMaitre Vascular by 26.2% in the third quarter. DF Dent & Co. Inc. now owns 258,767 shares of the medical instruments supplier’s stock worth $24,037,000 after purchasing an additional 53,797 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.